Enterprise Value

172.3M

Cash

95.2M

Avg Qtr Burn

-6.395M

Short % of Float

7.74%

Insider Ownership

5.03%

Institutional Own.

46.51%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details
Parkinson’s disease (OFF Episodes / motor fluctuations)

Approved

Quarterly sales

Exservan™ (riluzole) Oral Film Details
Amyotrophic Lateral Sclerosis (ALS)

Approved

Quarterly sales

Approved

Quarterly sales

NDA

Submission

Phase 1

Update

AQST-119 Details
Erectile dysfunction

Failed

Discontinued